MCRB

15.65

1.29% 0.20

Dopo l'orario di chiusura: 15.65

Seres Therapeutics Inc (MCRB)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$15.45

Aprire:

$15.43

Volume 24 ore:

22,748

Relative Volume:

0.15

Capitalizzazione di mercato:

$141.58M

Reddito:

$123.24M

Utile/perdita netta:

$136.00K

Rapporto P/E:

-782.50

EPS:

-0.02

Flusso di cassa netto:

$-148.99M

1 W Prestazione:

+3.30%

1M Prestazione:

-6.73%

6M Prestazione:

+26.41%

1 anno Prestazione:

-7.94%

Intervallo 1D:

$15.03

$15.68

Intervallo di 1 settimana:

$14.50

$16.30

Portata 52W:

$6.53

$29.98

Seres Therapeutics Inc Stock (MCRB) Company Profile

Nome

Seres Therapeutics Inc

Settore

Healthcare (1115)

Industria

Biotechnology (621)

Telefono

617 945 9626

Indirizzo

200 SIDNEY STREET, CAMBRIDGE, MA

Dipendente

103

Cinguettio

@SeresTX

Prossima data di guadagno

2024-10-31

Ultimi documenti SEC

MCRB's Discussions on Twitter

Confronta MCRB con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
MCRB Seres Therapeutics Inc	15.65	139.77M	123.24M	136.00K	-148.99M	-0.02
VRTX Vertex Pharmaceuticals Inc	463.86	119.17B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	796.55	84.19B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	398.29	52.77B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	788.49	48.98B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	175.97	36.31B	447.02M	-1.18B	-906.14M	-6.1812

Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-05-08	Downgrade	Chardan Capital Markets	Buy → Neutral
2024-10-24	Downgrade	JP Morgan	Neutral → Underweight
2023-06-26	Ripresa	Oppenheimer	Outperform
2023-04-21	Iniziato	JP Morgan	Neutral
2021-07-23	Downgrade	Goldman	Neutral → Sell
2021-05-18	Ripresa	Goldman	Neutral
2021-03-05	Aggiornamento	Chardan Capital Markets	Neutral → Buy
2020-09-18	Downgrade	Chardan Capital Markets	Buy → Neutral
2020-08-18	Iniziato	Piper Sandler	Overweight
2020-08-11	Reiterato	H.C. Wainwright	Buy
2020-08-11	Aggiornamento	Jefferies	Hold → Buy
2019-04-30	Iniziato	Jefferies	Hold
2018-10-22	Iniziato	Chardan Capital Markets	Buy
2017-10-13	Iniziato	Oppenheimer	Outperform
2017-08-04	Reiterato	H.C. Wainwright	Buy
2017-02-01	Reiterato	FBR & Co.	Outperform
2016-08-12	Reiterato	FBR Capital	Outperform
2016-08-01	Downgrade	BofA/Merrill	Buy → Neutral
2016-08-01	Reiterato	H.C. Wainwright	Buy
2016-07-29	Ripresa	H.C. Wainwright	Buy
2016-03-30	Iniziato	FBR Capital	Outperform
2016-03-03	Iniziato	Guggenheim	Buy
2016-01-25	Iniziato	H.C. Wainwright	Buy
2015-10-22	Aggiornamento	BofA/Merrill	Neutral → Buy
2015-07-22	Iniziato	Canaccord Genuity	Buy
2015-07-21	Iniziato	Goldman	Neutral
2015-07-21	Iniziato	Leerink Partners	Outperform

Mostra tutto

Seres Therapeutics Inc Borsa (MCRB) Ultime notizie

Jan 09, 2026

Will Seres Therapeutics Inc. stock deliver better than expected guidanceWeekly Market Summary & Free High Accuracy Swing Entry Alerts - ulpravda.ru

Jan 09, 2026

Jan 07, 2026

Seres Therapeutics, Inc.Common Stock (NQ: MCRB - FinancialContent

Jan 07, 2026

Why Seres Therapeutics Inc. stock is in analyst buy zoneBearish Engulfing Patterns & Big Gains Small Capital - ulpravda.ru

Jan 07, 2026

Seres Therapeutics publishes new insights on VOWST mechanism By Investing.com - Investing.com Nigeria

Jan 07, 2026

Jan 06, 2026

Seres Therapeutics expands board, appoints new director - MSN

Jan 06, 2026

Seres Therapeutics publishes new insights on VOWST mechanism - Investing.com

Jan 06, 2026

Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy - GlobeNewswire

Jan 06, 2026

Jan 02, 2026

Seres Therapeutics Q1 2025 Earnings Preview - MSN

Jan 02, 2026

Jan 01, 2026

Why Seres Therapeutics Inc. stock is rated strong buyInterest Rate Changes & Minimal Risk High Reward - bollywoodhelpline.com

Jan 01, 2026

Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 50-Day Moving AverageHere's Why - MarketBeat

Jan 01, 2026

Dec 29, 2025

3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround - The Globe and Mail

Dec 29, 2025

Dec 24, 2025

Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below 50 Day Moving AverageShould You Sell? - MarketBeat

Dec 24, 2025

Dec 20, 2025

How Seres Therapeutics Inc. stock responds to policy changesGlobal Markets & Verified Entry Point Detection - Улправда

Dec 20, 2025

Dec 19, 2025

The Great Biotech Re-Shoring: Seres Therapeutics and the New Commodity-Driven Era - FinancialContent

Dec 19, 2025

Can Seres Therapeutics Inc. (1S90) stock stage a strong rebound this quarterMarket Volume Report & Fast Gain Swing Alerts - DonanımHaber

Dec 19, 2025

Why analysts remain bullish on Seres Therapeutics Inc. stockRate Cut & Daily Profit Focused Stock Screening - DonanımHaber

Dec 19, 2025

Dec 18, 2025

Is Seres Therapeutics Inc. stock affected by interest rate hikesCPI Data & Weekly Return Optimization Alerts - Улправда

Dec 18, 2025

Will Seres Therapeutics Inc. stock gain from government policiesJuly 2025 Market Mood & Weekly Top Stock Performers List - Улправда

Dec 18, 2025

Dec 17, 2025

Seres Therapeutics Cuts Costs to Extend Cash Runway - MSN

Dec 17, 2025

Dec 16, 2025

Head-To-Head Contrast: Castle Biosciences (NASDAQ:CSTL) versus Seres Therapeutics (NASDAQ:MCRB) - Defense World

Dec 16, 2025

Dec 14, 2025

North America Human Microbiome Market Size & Growth Forecast to 2031 - MarketsandMarkets

Dec 14, 2025

Dec 13, 2025

Guidance Update: How Seres Therapeutics Inc 1S90 stock compares with market leaders2025 Biggest Moves & Long-Term Growth Stock Strategies - moha.gov.vn

Dec 13, 2025

Published on: 2025-12-13 20:57:20 - moha.gov.vn

Dec 13, 2025

Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Above 50 Day Moving AverageHere's What Happened - MarketBeat

Dec 13, 2025

Dec 07, 2025

Seres Therapeutics (MCRB) price target increased by 31.25% to 21.42 - MSN

Dec 07, 2025

Dec 05, 2025